Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions

Journal of Dermatology

Volumn 43, Issue 6, 2016, Pages 620-632

  Alpsoy, Erkan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; clinical course; epidemiology; etiology; treatment

Indexed keywords

APREMILAST; AZATHIOPRINE; BENZATHINE PENICILLIN; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DAPSONE; ETANERCEPT; HLA B51 ANTIGEN; INTERFERON; INTERLEUKIN 17; ISOTRETINOIN; LISTERINE; PLACEBO; PREDNISOLONE; REBAMIPIDE; RITUXIMAB; SECUKINUMAB; THALIDOMIDE; ZINC SULFATE; IMMUNOSUPPRESSIVE AGENT;

BEHCET DISEASE; CLINICAL FEATURE; DISEASE COURSE; ERYTHEMA NODOSUM; GENETIC ASSOCIATION; GENITAL ULCER; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HLA B51 GENE; HUMAN; IMMUNOPATHOLOGY; LABORATORY TEST; MORTALITY; MOUTH ULCER; PREVALENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; SKIN PATHERGY TEST; SKIN TEST; TH17 CELL; THROMBOPHLEBITIS; BEHCET SYNDROME; MOUTH MUCOSA; PATHOLOGY; SKIN;

BEHCET SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOUTH MUCOSA; SKIN;

EID: 84963800130     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13381     Document Type: Review

References (120)

1. Behçet H,. Uber rezidivierende aphthöse, durch ein Virus verursachte Geschwure, am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157.
2. Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O,. CTLA-4 gene 49A/G polymorphism in Turkish patients with Behçet's disease. Clin Exp Dermatol 2005; 30: 546-550.
3. Alpsoy E, Zouboulis CC, Ehrlich CE,. Mucocutaneous lesions of Behçet's disease. Yonsei Med J 2007; 48: 573-585.
4. Cho SB, Cho S, Bang D,. New insights in the clinical understanding of Behçet's disease. Yonsei Med J 2012; 53: 35-42.
5. Azizlerli G, Kose AA, Sarica R, et al,. Prevalence of Behcet's disease in Istanbul, Turkey. Int J Dermatol 2003; 42: 803-806.
6. Sakane T, Takeno M, Suzuki N, Inaba G,. Behcet's disease. N Engl J Med 1999; 341: 1284-1291.
7. Dalvi SR, Yildirim R, Yazici Y,. Behcet's syndrome. Drugs 2012; 72: 2223-2241.
8. Hirohata T, Kuratsume M, Nomura A, Jimi S,. Prevalence of Behçet's syndrome in Hawaii, with particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J 1975; 34: 244-246.
9. Papoutsis NG, Abdel-Naser MB, Altenburg A, et al,. Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 2006; 24 (5 Suppl 42): S125.
10. Mahr A, Belarbi L, Wechsler B, et al,. Population-based prevalence study of Behçet's disease differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58: 3951-3959.
11. Alpsoy E, Donmez L, Onder M, et al,. Clinical features and natural course of Behcet's disease in 661 cases: a multicentre study. Br J Dermatol 2007; 157: 901-906.
12. Balta I, Akbay G, Kalkan G, Eksioglu M,. Demographic and clinical features of 521 Turkish patients with Behçet's disease. Int J Dermatol 2014; 53: 564-569.
13. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y,. Behçet disease: evolution of clinical manifestations. Medicine (Baltimore) 2011; 90: 125-132.
14. Skef W, Hamilton MJ, Arayssi T,. Gastrointestinal Behçet's disease: a review. World J Gastroenterol 2015; 21: 3801-3812.
15. Nishiyama M, Nakae K, Takahashi M, Kuriyama T,. A study of clinical features and the worsening factors among patients with Behcet's disease in Japan. Dokkyo J Med Sci 2003; 30: 237-242.
16. Yazici H, Tüzün Y, Tanman AB, et al,. Male patients with Behçet's syndrome have stronger pathergy reactions. Clin Exp Rheumatol 1985; 3: 137-141.
17. Dilsen N, Koniçe M, Aral O, Aykut S,. Standardization and evaluation of the skin pathergy test in Behçet's disease and controls. In:, Lehner T, Barnes CG, eds. Recent Advances in Behçet's Disease. London: Royal Society of Medicine Services, 1986; 169-172.
18. Davatchi F, Shahram F, Chams-Davatchi C, et al,. Behcet's disease in Iran. Analysis of 6500 cases. Int J Rheum Dis 2010; 13: 367-373.
19. Togashi A, Saito S, Kaneko F, Nakamura K, Oyama N,. Skin prick test with self-saliva in patients with oral aphthoses: a diagnostic pathergy for Behcet's disease and recurrent aphthosis. Inflamm Allergy Drug Targets 2011; 10: 164-170.
20. Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E,. Relationship between periodontal findings and Behcet's disease: a controlled study. J Clin Periodontol 2007; 34: 485-491.
21. Eglin RP, Lehner T, Subak-Sharpe JH,. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet 1982; 2: 1356-1361.
22. Lehner T,. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997; 14: 21-32.
23. Mumcu G, Ergun T, Inanc N, et al,. Oral health is impaired in Behcet's disease and is associated with disease severity. Rheumatology 2004; 43: 1028-1033.
24. Kaneko F, Oyama N, Nishibu A,. Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997; 38: 444-454.
25. Mizushima Y, Matsuda T, Hoshl K, Ohno S,. Induction of Behcet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1998; 15: 1029-1030.
26. Alpsoy E,. Behçet's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 2005; 23: 532-539.
27. Celenligil-Nazliel H, Kansu E, Ebersole J,. Periodontal findings and systemic antibody responses to oral microorganisms in Behcet's disease. J Periodontol 1999; 70: 1449-1456.
28. Karacayli U, Mumcu G, Simsek I, et al,. The close association between dental and periodontal treatments and oral ulcer course in behcet's disease: a prospective clinical study. J Oral Pathol Med 2009; 38: 410-415.
29. Kaneko F, Togashi A, Nomura E, Nakamura K,. A new diagnostic way for Behcet's disease: skin prick with self-saliva. Genet Res Int 2014; 2014: 581468.
30. Akman A, Sallakci N, Kacaroglu H, et al,. Relationship between periodontal findings and the TNF-alpha Gene 1031T/C polymorphism in Turkish patients with Behçet's disease. J Eur Acad Dermatol Venereol 2008; 22: 950-957.
31. Gul A, Inanc M, Ocal L, Aral O, Konice M,. Familial aggregation of Behcet's disease in Turkey. Ann Rheum Dis 2000; 59: 622-625.
32. Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K, Aizawa M,. HLA-5 and Behcet's disease. Lancet 1973; ii: 1383-1384.
33. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A,. HLA-B51/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61: 1287-1296.
34. Hughes T, Coit P, Adler A, et al,. Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet 2013; 45: 319-324.
35. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH,. Identification of novel genetic susceptibility loci for Behcet's disease using a genome-wide association study. Arthritis Res Ther 2009; 11: R66.
36. Remmers EF, Cosan F, Kirino Y, et al,. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010; 42: 698-702.
37. Mizuki N, Meguro A, Ota M, et al,. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010; 42: 703-706.
38. Hou S, Yang Z, Du L, et al,. Identification of a susceptibility locus in STAT4 for Behcet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum 2012; 64: 4104-4113.
39. Lee YJ, Horie Y, Wallace GR, et al,. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis 2013; 72: 1510-1516.
40. Kirino Y, Bertsias G, Ishigatsubo Y, et al,. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B-51 and ERAP1. Nat Genet 2013; 45: 202-207.
41. Alpsoy E, Akman A,. Treatment of Behçet's disease. Therapy 2006; 3: 139-151.
42. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K,. Cytokine profile in Behçet's disease patients: relationship with disease activity. J Rheumatol 2002; 31 205-210.
43. Chi W, Zhu X, Yang P, et al,. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49: 3058-3064.
44. Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O,. IL-17A has an important role in the acute attacks of Behçet's disease. J Invest Dermatol 2010; 130: 2136-2138.
45. Main DM, Chamberlain MA,. Clinical differentiation of oral ulceration in Behcet's disease. Br J Rheumatol 1992; 31: 767-770.
46. Kim B, LeBoit PE,. Histopathologic features of erythema nodosum-like lesions in Behcet disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol 2000; 22: 379-390.
47. Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E,. A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet's patients. Int J Dermatol 1998; 37: 839-843.
48. Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H,. Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001; 60: 1074-1076.
49. Jennette JC, Falk RJ, Bacon PA, et al,. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
50. Sarica-Kucukoglu R, Akdag-Kose A, KayabalI M, et al,. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006; 45: 919-921.
51. Lee ES, Bang D, Lee S,. Dermatologic manifestation of Behçet's disease. Yonsei Med J 1997; 38: 380-389.
52. Ugurlu N, Bozkurt S, Bacanli A, Akman-Karakas A, Uzun S, Alpsoy E,. The natural course and factors affecting severity of Behçet's disease: a single-center cohort of 368 patients. Rheumatol Int 2015; 35: 2103-2107.
53. Kural-Seyahi E, Fresko I, Seyahi N, et al,. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
54. Pipitone N, Boiardi L, Olivieri I, et al,. Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol 2004; 22 (6 Suppl 36): S46-S51.
55. Yazici H, Tuzun Y, Pazarli H, et al,. Influence of age of onset and patient's sex on the prevalans and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-789.
56. Bonitsis NG, Luong Nguyen LB, LaValley MP, et al,. Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology (Oxford) 2015; 54: 121-133.
57. Bang DS, Oh SH, Lee KH, Lee ES, Lee SN,. Influence of sex on patients with Behcet's disease in Korea. J Korean Med Sci 2003; 18: 231-235.
58. Alli N, Gur G, Yalcin B, Hayran M,. Patient characteristics in Behçet disease: a retrospective analysis of 213 Turkish patients during 2001-4. Am J Clin Dermatol 2009; 10: 411-418.
59. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
60. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338-347.
61. Yazici H, Yazici Y,. Criteria for Behçet's disease with reflections on all disease criteria. J Autoimmun 2014; 48-49: 104-107.
62. Mizushima Y,. Recent research into Behcet's disease in Japan. Int J Tissue React 1988; 10: 59-65.
63. Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis C,. Serum of patients with Behçet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003; 206: 225-232.
64. Alpsoy E, Uzun S, Akman A, Acar MA, Memi?oglu HR, Ba?aran E,. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2003; 17: 521-524.
65. Jorizzo JL, Abernethy JL, White WL, et al,. Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995; 32: 968-976.
66. Alpsoy E,. New evidence-based treatment approach in Behçet's disease. Patholog Res Int 2012; 2012: 871019.
67. Alpsoy E, Akman A,. Behçet's disease: an algorithmic approach to its treatment. Arch Dermatol Res 2009; 301: 693-702.
68. Hatemi G, Silman A, Bang D, et al,. EULAR recommendations for the management of Behcet's disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008; 67: 1656-1662.
69. Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG, Siegel MA,. Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol 1991; 72: 425-429.
70. Addy M, Carpenter R, Roberts WR,. Management of recurrent aphthous ulceration. A trial of chlorhexidine gel. Br Dent J 1976; 141: 118-120.
71. Kerr AR, Drexel CA, Spielman AI,. The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 685-694.
72. Graykowski EA, Kingman A,. Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 1978; 7: 376-382.
73. Henricsson V, Axéll T,. Treatment of recurrent aphthous ulcers with aureomycin mouth rinse or Zendium dentifrice. Acta Odontol Scand 1985; 43: 47-52.
74. Skaare AB, Herlofson BB, Barkvoll P,. Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol 1996; 23: 778-781.
75. Alpsoy E, Er H, Durusoy C, Yilmaz E,. The use of sucralfate suspension in the treatment of oral and genital ulcerations of Behçet's disease: a randomised, placebo-controlled and double-blind study. Arch Dermatol 1999; 135: 529-532.
76. Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S,. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behcet's syndrome. Iran Red Crescent Med J 2012; 14: 75-78.
77. Al-Na'mah ZM, Carson R, Thanoon IA,. Dexamucobase: a novel treatment for oral aphthous ulceration. Quintessence Int 2009; 40: 399-404.
78. Liu J, Zeng X, Chen Q, et al,. An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 475-481.
79. Binnie WH, Curro FA, Khandwala A, Van Inwegan RG,. Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent 1997; 18: 1116-1124.
80. Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A,. A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg 1993; 51: 243-248.
81. Collier PM, Neill SM, Copeman PW,. Topical 5-aminosalicylic acid: a treatment for aphthous ulcers. Br J Dermatol 1992; 126: 185-188.
82. Köse O, Dinç A, Simşek I,. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease. Dermatology 2009; 218: 140-145.
83. Chams-Davatchi C, Barikbin B, Shahram F, et al,. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Int J Rheum Dis 2010; 13: 253-258.
84. Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N,. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 2007; 13: 1.
85. Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E,. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dentist 2008; 28: 27-31.
86. Pourahmad M, Rahiminejad M, Fadaei S, Kashafi H,. Effects of camel thorn distillate on recurrent oral aphthous lesions. J Dtsch Dermatol Ges 2010; 8: 348-352.
87. Saxen MA, Ambrosius WT, al Rehemtula KF, Russell AL, Eckert GJ,. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 356-361.
88. Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ,. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005; 153: 521-525.
89. Zand N, Ataie-Fashtami L, Djavid GE, et al,. Relieving pain in minor aphthous stomatitis by a single session of non-thermal carbon dioxide laser irradiation. Lasers Med Sci 2009; 24: 515-520.
90. Arabaci T, Kara C, Cicek Y,. Relationship between periodontal parameters and Behçet's disease and evaluation of different treatments for oral recurrent aphthous stomatitis. J Periodontal Res 2009; 44: 718-725.
91. Aktulga E, Altac M, Muftuoglu A, et al,. A double blind study of colchicine in Behcet's disease. Haematologica 1980; 65: 399-402.
92. Yurdakul S, Mat C, Tuzun Y, et al,. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001; 44: 2686-2692.
93. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al,. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19: 542-549.
94. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I,. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology 1996; 192: 125-128.
95. Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK,. Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J 2005; 11: 3.
96. Mat C, Yurdakul S, Ozyazgan Y, Uysal S, Uysal O, Yazbox drawings light down and leftcbox drawings light down and left H,. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006; 45: 348-352.
97. Sharquie KE, Najim RA, Abu-Raghif AR,. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002; 29: 267-279.
98. Yazici H, Pazarli H, Barnes CG, et al,. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990; 322: 281-285.
99. Hamuryudan V, Mat C, Saip S, et al,. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-450.
100. Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK,. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study. J Dermatol 2006; 33: 541-546.
101. Matsuda T, Ohno S, Hirohata S, et al,. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003; 4: 19-28.
102. Assaad-Khalil SH,. Low-dose cyclosporin in Behçet's disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behçet's disease. In:, O'Duffy JD, Kokmen E, eds. Behçet's Disease: Basic and Clinical Aspects. New York: Marcel Dekker, 1991; 603-612.
103. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G,. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989; 20: 1093-1096.
104. Hatemi G, Melikoglu M, Tunc R, et al,. Apremilast for Behçet's syndrome-a phase 2, placebo-controlled study. N Engl J Med 2015 Apr; 16 (372): 1510-1518.
105. Alpsoy E, Durusoy C, Yilmaz E, et al,. Interferon alpha-2a in the treatment of Behçet disease: a randomized, placebo-controlled and double blind study. Arch Dermatol 2002; 138: 467-471.
106. Melikoglu M, Fresko I, Mat C, et al,. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
107. Sharquie KE, Helmi RM, Noiami AA, Al-Hayani RK, Kadhom MA,. The therapeutic role of isotretinoin in the management of Behçet's disease: a single-blinded, controlled therapeutic study. J Drugs Dermatol 2013; 12: e68-e73.
108. BenEzra D, Cohen E, Chajek T, et al,. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988; 20: 136-143.
109. Elidan J, Cohen E, Levi H, BenEzra D,. Effect of cyclosporine A on the hearing loss in Behçet's disease. Ann Otol Rhinol Laryngol 1991; 100: 464-468.
110. Ozyazgan Y, Yurdakul S, Yazici H, et al,. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992; 76: 241-243.
111. Davatchi F, Shahram F, Chams H, Akbarian M,. Pulse cyclophosphamide (PCP) for ocular lesions of Behçet's disease: double blind crossover study. Arthritis Rheum 1999; 42: S320.
112. Davatchi F, Shams H, Rezaipoor M, et al,. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13: 246-252.
113. Dick AD, Tugal-Tutkun I, Foster S, et al,. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120: 777-787.
114. Buggage RR, Levy-Clarke G, Sen HN, et al,. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007; 15: 63-70.
115. Sfikakis PP, Markomichelakis N, Alpsoy E, et al,. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-741.
116. Vitale A, Rigante D, Caso F, et al,. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. Dermatology 2014; 228: 211-214.
117. Cantarini L, Vitale A, Scalini P, et al,. Anakinra treatment in drug-resistant Behçet's disease: a case series. Clin Rheumatol 2015; 34: 1293-1301.
118. Diamantopoulos AP, Hatemi G,. Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. Rheumatology (Oxford) 2013; 52: 1923-1924.
119. Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP,. Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 2013; 72: 626-627.
120. Zhao BH, Oswald AE,. Improved clinical control of a challenging case of Behçet's disease with rituximab therapy. Clin Rheumatol 2014; 33: 149-150.